Ortho Classic Appoints Jeff Tunnel As Vice President Of Sales

MCMINNVILLE, Ore., Sept. 15, 2015 /PRNewswire/ -- Ortho Classic has named Jeff Tunnell as Vice President of Sales. In this role, he will lead all aspects of the domestic sales for Ortho Classic.

Jeff Tunnell, Vice President of Sales, carries a broad base of experience with both Fortune 500 companies as well as startup companies introducing new disruptive technology within the medical device arena.  Tunnell has excellent team building leadership skills creating highly successful sales teams to supercharge sales revenues growth.

"Jeff is an outstanding addition to our Ortho Classic team, as he brings a deep blend of both medical and dental sales management experience," said Rolf Hagelganz, CEO of Ortho Classic. "In his new role, Jeff will support Ortho Classic with aggressive growth strategies, which include increasing the sales force to better assist our expanding customer base and supporting all initiatives developed by our marketing department."

About Ortho Classic

Ortho Classic produces and distributes some of the highest quality products on the market. Manufactured in the U.S.A., high quality doesn't always have to mean a high price. From brackets to buccal tubes and elastics to instruments, Ortho Classic is your one-stop orthodontic resource in 85 countries around the world. Find out more at http://www.orthoclassic.com

Media Contact:
Alexandra B Mazzi
512-9478916
Email

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ortho-classic-appoints-jeff-tunnel-as-vice-president-of-sales-300143005.html

SOURCE Ortho Classic

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.